Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-09-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It details the stock suspension, progress updates on the restructuring, and the reasons for the delay in replying to the inquiry. The document does not contain financial statements or detailed financial data but is a regulatory announcement about the status of a restructuring process and stock suspension. It fits the category of a Regulatory Filing (RNS) as it is a compliance and status update rather than a full report or financial disclosure.
2017-09-11 Chinese
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It details the stock suspension, progress updates on the restructuring, and the reasons for the delay in replying to the inquiry. The document does not contain financial statements or detailed financial data but is a regulatory announcement about the status of a corporate action and stock suspension. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about the company's compliance and disclosure obligations related to the restructuring inquiry and stock suspension.
2017-09-04 Chinese
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It details the history of the stock suspension, progress updates on the restructuring, and the reasons for the delay in replying to the inquiry. The document does not contain financial statements or detailed financial data but is focused on regulatory communication about the restructuring process and stock suspension. It is not a full report like an Annual Report or Interim Report, nor is it a direct financial disclosure. It is an official regulatory announcement about the status of a major corporate action and related stock suspension. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-08-28 Chinese
关于2017年股票期权激励计划股票期权授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the completion of the registration of stock options granted under a 2017 stock option incentive plan. It details the approval procedures, the number of stock options granted, the exercise price, the exercise schedule, and performance conditions. The document is a formal public disclosure about the stock option grant event, not a full financial report or management discussion. It does not contain financial statements or earnings data, nor is it a meeting presentation or voting result. It is a regulatory announcement about a capital-related incentive plan, specifically about stock option grants and their registration completion. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including stock option plans.
2017-08-23 Chinese
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It details the stock suspension, progress updates, and regulatory approvals pending for the restructuring. The document is relatively short (1874 characters) and primarily serves as a formal announcement about the status of the restructuring and stock suspension, not a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis but rather updates on regulatory and procedural matters. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2017-08-21 Chinese
第三届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the approval of a stock option incentive plan for 2017. It includes details about the meeting date, participants, compliance with relevant laws, and the approval of granting stock options to employees. The document does not contain financial statements or detailed financial analysis but is an official announcement of a board decision related to stock incentives. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting result announcement. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about corporate governance and stock option grants without detailed financial data or report publication.
2017-08-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.